18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors

Annals of Nuclear Medicine

Volumn 25, Issue 4, 2011, Pages 247-253

  Kaira, Kyoichi ^a   Murakami, Haruyasu ^a   Miura, Satoru ^a   Kaira, Rieko ^a   Akamatsu, Hiroaki ^a   Kimura, Madoka ^a   Ono, Akira ^a   Tsuya, Asuka ^a   Nakamura, Yukiko ^a   Naito, Tateaki ^a   Takahashi, Toshiaki ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Keywords 18F FDG PET; Metabolic response; Monitoring; Therapy response; Thymic epithelial tumor

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; VINCRISTINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; EPITHELIUM TUMOR; FEMALE; HUMAN; MALE; METABOLIC DISORDER; NEEDLE BIOPSY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; THYMIC EPITHELIAL TUMOR; THYMOMA; THYMUS CANCER; THYMUS CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; METABOLISM; MIDDLE AGED; NEOPLASM; RETROSPECTIVE STUDY; SCINTISCANNING; SURVIVAL;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 79959919117     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-010-0455-x     Document Type: Article

References (19)

1. 18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005; 23: 1136-43. (Pubitemid 46202269)
2. 18F-fluoro-2-deoxy-glucose-positron emission tomography in non-small cell lung cancer: an analysis of 125 cases. J Clin Oncol. 1999; 17: 3201-6. (Pubitemid 29470652)
3. Berghmans T, DusartM, PaesmansM, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in nonsmall cell lung cancer (NSCLC): a systematic review and metaanalysis (MA) by the European lung cancer working party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008; 3: 6-12.
4. 18F] fluorodeoxygluose. J Clin Oncol. 2006; 24: 4587-93. (Pubitemid 46630956)
5. 18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010; 28: 3746-53.
6. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981; 48: 2485-92. (Pubitemid 12228012)
7. Rosai J, Sobin LH. Histological typing of tumours of the thymus, International histological classification of tumours. 2nd ed. New York: Springer; 1999. p. 1-59.
8. Travis WD, Brambillia E, Muller-Hermelink HK. WHO classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-16. (Pubitemid 30099779)
10. 18F] luorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer. J Clin Oncol. 2007; 25: 3116-23. (Pubitemid 47218060)
11. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999; 35: 1773-82. (Pubitemid 29512308)
12. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERSIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50(Suppl): 122S-47S.
13. 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer. 2008; 61: 350-5.
14. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer. A systematic review. Cancer. 2007; 110: 1654-64. (Pubitemid 47557290)
15. Pö ttgen C, Levegrü n S, Theegarten D, Marnitz S, Grehl S, Pink R, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006; 12: 97-106. (Pubitemid 43166182)
16. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004; 78: 1903-9. (Pubitemid 39556258)
17. 18F-FDG PET/CT of thymic epithelial tumors: usefulness of distinguishing and staging tumor subgroups. J Nucl Med. 2006; 47: 1628-34. (Pubitemid 47545028)
18. El-Bawab H, Al-Sugair AA, Rafay M, Choi JY, Shim YM, Yi CA. Role of fluorine-18 fluorodeoxyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg. 2007; 31: 731-6. (Pubitemid 46400514)
19. 18FDG PET-CT. Ann Nucl Med. 2009; 23: 569-77.